The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter, randomized phase II study of rilotumumab (R) (AMG 102) or placebo (Pbo) plus mitoxantrone (M) and prednisone (P) in patients (pts) with previously treated castrate-resistant prostate cancer (CRPC).
Charles J. Ryan
No relevant relationships to disclose
Mark Rosenthal
No relevant relationships to disclose
Siobhan Ng
Consultant or Advisory Role - Amgen (U)
Research Funding - Amgen
Other Remuneration - Amgen
Joshi J. Alumkal
No relevant relationships to disclose
Joel Picus
No relevant relationships to disclose
Gwenaelle Gravis
No relevant relationships to disclose
Karim Fizazi
Consultant or Advisory Role - Amgen (U)
Frederic Forget
Other Remuneration - Amgen
Jean-Pascal H. Machiels
No relevant relationships to disclose
Min Zhu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Joe Jiang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Sarita Dubey
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Elwyn Loh
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Winald R. Gerritsen
Consultant or Advisory Role - Amgen (U)
Honoraria - Amgen